For patients with stage IV NSCLC carrying EGFR active mutations, a single arm phase II clinical trial (NCT02353741) showed that patients received EGFR-TKI (Erlotinib 150mg/d or Gefitinib 250mg/d) and chest radiotherapy (54-60Gy/27-30 F/5.5-6 weeks) within 2 weeks after starting EGFR-TKI treatment, with a 1-year PFS rate of 57.1% and a median PFS of 13 months, both higher than Erlotinib monotherapy (43% and 11 months). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.